We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

By LabMedica International staff writers
Posted on 04 Feb 2026

Alzheimer’s disease affects approximately 6. More...

7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests that imbalances in the gut microbiome—known as dysbiosis—may contribute to the onset and progression of mild cognitive impairment (MCI) and Alzheimer’s disease.

Researchers are increasingly focused on the microbiota–gut–brain axis, a complex network linking the gut, immune system, and brain. Disruptions in this system are thought to promote neuroinflammation, leading to damage of nerve cells and potentially accelerating cognitive decline associated with Alzheimer’s disease. New research has revealed reproducible bacterial and functional signatures linking gut microbiome dysbiosis to MCI and Alzheimer’s disease.

George Washington University (Washington, DC, USA) researchers analyzed 58 human studies published through February 2023, constituting the most comprehensive human-only review in this area. Published January 22, 2026 in Alzheimer’s & Dementia, the work assessed microbiome composition, diversity, and predicted function. 

Across multiple studies, people with mild cognitive impairment and Alzheimer’s disease consistently exhibited gut microbiota profiles that differed from those of cognitively healthy older adults. Alzheimer’s disease was associated with higher levels of certain bacterial groups, particularly the phyla Pseudomonadota and Actinomycetota. In addition, some individuals with Alzheimer’s disease showed reduced gut microbial diversity, meaning they had fewer types of bacteria than typically observed.

The types and relative abundance of gut bacteria differ among people with MCI, Alzheimer’s disease, and cognitively healthy individuals, suggesting distinct microbiome signatures at different stages of cognitive decline. In people with Alzheimer’s disease, functional alterations in gut bacteria have also been observed, including reduced activity in pathways related to energy production and immune function.

Although the review does not establish a cause-and-effect relationship, its findings are consistent with broader evidence indicating that diets high in fiber may promote a healthier gut microbiome, with possible downstream benefits for inflammation and brain health.

“While these early, largely observational results are encouraging, we need clinical trials to determine whether microbiome-targeted interventions can meaningfully alter disease trajectories. These trials are already underway in our lab and labs around the world.” said lead researcher Leigh Frame, associate professor in the George Washington University School of Medicine and Health Sciences. 

Related Links
GW School of Medicine & Health Science


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.